1356P Cumulative incidence and baseline imaging patterns of brain metastases in advanced EGFR and ALK positive non-small cell lung cancer (NSCLC)

Background: Up to 40% of NSCLC patients develop brain metastases (mets) during the course of their disease. We explored the impact of histology and EGFR and ALK mutations on cumulative incidence rates of brain mets and influence of brain imaging patterns. Conclusions: Our real-world data confirm a higher cumulative incidence of brain metastases in EGFR+/ALK+ adenocarcinoma compared to WT or SCC and more brain imaging at baseline. Future analyses will focus on treatment-based outcomes (tyrosine kinase inhibitors, different radiation modalities) in EGFR+/ALK+ patients compared to WT adenocarcinoma and SCC. READ ARTICLE

Annals of Oncology DOI:10.1016/j.annonc.2021.08.1956

Authors: M.T. Chowdhury, M. García Pardo de Santayana, S. Schmid, S. Cheng, L.J. Zhan, M.C. Brown, K. Khan, P. Walia, A. Sabouhanian, E. Strom, J. Herman, N. Leighl, P. Bradbury, F.A. Shepherd, A. Sacher, W. Xu, G. Liu, D. Shultz

Conference PaperKirk SmithSeptember 1, 2021Cumulative incidence, baseline imaging patterns, brain metastases, EGFR, ALK, non-small cell lung cancer (NSCLC)

Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis

In this study, we confirmed that there is an increased incidence of TTE in both ALK+ and ROS1+ NSCLC patients as compared to controls (non-ALK+ and non-ROS1+) by meta-analysis. Additionally, time-to-event analysis in this study served as a second meta-analytic method to provide dual sensitivity and confirmed similar elevated TTE risks among ALK+ and ROS1+ NSCLC patients. VTE (primarily PE and DVT) is the primary TE event of interest investigated in the studies included in this systematic review. In general, this meta-analysis indicated there is about a 2.5-fold and slightly higher than 3-fold increase in VTE among ALK+ and ROS1+ patients, respectively when compared to non-ALK+ and non-ROS1+ NSCLC patients. READ ARTICLE

Lung Cancer DOI:10.1016/j.lungcan.2021.05.019

Authors: Viola W. Zhu, Joseph J. Zhao, Yanfei Gao, Nicholas L. Syn, Shannon S. Zhang, Sai-Hong Ignatius Ou, Kenneth A. Bauer, Misako Nagasaka

Review PaperKirk SmithMay 1, 2021ALK+ NSCLC, Meta-analysis, Systematic review, Cumulative incidence, Thromboembolism, Pulmonary embolism, Deep vein thrombosis